Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (899)	11/26/1997 12:45:00 PM
From: Banjoman	Read Replies (2) \| Respond to of 1359

FWIW: Just noticed a Lehman Bros report (available on-line) on IPIC. Lehman has IPIC rated 1-Buy. Analyst says "Interneuron's stock has been hampered by the potential liability of Redux. Our due diligence suggests that the probability that Interneuron is found negligent is minimal." It is comforting to hear that from another source. The analyst (CA Butler and R. Rouse) say later in the note that they believe that early 98 data from two ongoing trials of Redux will create an early settlement of the liability claims thus minimizing IPIC's legal expenses, and argue that IPIC has sufficient value x-Redux to justify a target price of 33. lehman.com